KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Expenses (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Operating Expenses for 7 consecutive years, with $233.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 0.64% to $233.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $818.7 million through Dec 2025, down 15.7% year-over-year, with the annual reading at $818.7 million for FY2025, 15.7% down from the prior year.
  • Operating Expenses hit $233.6 million in Q4 2025 for Royalty Pharma, up from $182.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.0 billion in Q4 2022 to a low of -$190.0 million in Q2 2021.
  • Historically, Operating Expenses has averaged $272.1 million across 5 years, with a median of $275.2 million in 2021.
  • Biggest five-year swings in Operating Expenses: tumbled 287.02% in 2021 and later surged 1479.41% in 2024.
  • Year by year, Operating Expenses stood at $422.3 million in 2021, then soared by 148.27% to $1.0 billion in 2022, then tumbled by 101.61% to -$16.8 million in 2023, then soared by 1479.41% to $232.1 million in 2024, then increased by 0.64% to $233.6 million in 2025.
  • Business Quant data shows Operating Expenses for RPRX at $233.6 million in Q4 2025, $182.1 million in Q3 2025, and $368.9 million in Q2 2025.